SCHEMBL2864066

SCHEMBL2864066

CC(CS)N(C(=O)Oc1ccc(-c2cc(O)no2)cc1)c1ccc2ncsc2c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 2/20 0.37
PDE10A Q9Y233 5/20 0.36
TP53 P04637 4/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 2/20 0.35
THRB P10828 2/20 0.35
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HPGD P15428 2/20 0.33
FFAR1 O14842 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPK1 P28482 1/20 0.32
STAT1 P42224 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3407756 0.84 SMPD1 (0.34) SMPD1TP53MAPTLMNATHRB
SCHEMBL2855118 0.83 NPC1 (0.41) PDE10ANPC1RAB9AMEN1KMT2A
SCHEMBL2869557 0.82 GFER (0.40) PDE10ANPC1RAB9ASMN1; SMN2FFAR1
SCHEMBL2862160 0.82 PDE10A (0.35) SMPD1PDE10ATP53MAPTLMNA
SCHEMBL2866012 0.82 PDE10A (0.39) PDE10ATP53MAPTLMNANPC1
SCHEMBL2855234 0.81 MEN1 (0.44) PDE10AMAPTNPC1RAB9AMEN1
SCHEMBL2862836 0.80 ALDH1A1 (0.40) PDE10ANPC1RAB9AMEN1KMT2A
SCHEMBL2858382 0.80 ALDH1A1 (0.40) PDE10ATP53LMNA
SCHEMBL2859516 0.79 PDE10A (0.37) PDE10ANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3433640 0.78 MEN1 (0.37) PDE10ATP53MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-7709510-B2 Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-05-04 US claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 SMPD1 644/4885PDE10A 3156/4885TP53 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.